CreamMRP Under Process
Official PMBI MRP is being updated for catalog code 2322.
Locate Jan Aushadhi KendraClinical Overview
Hydrocortisone Acetate (1% w/w) is a low-potency (Class VII) topical corticosteroid on the WHO Model List of Essential Medicines. It represents the safest topical steroid for sensitive skin areas (face, intertriginous skin folds, groin) and pediatric patients, providing anti-inflammatory, anti-pruritic, and mild vasoconstrictive actions with minimal risk of skin thinning or systemic absorption. Indicated for mild eczema, facial dermatitis, intertrigo, insect bites, and anogenital pruritus.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Apply sparingly to affected areas 2 to 3 times daily. Gently rub in. May be used on facial skin for short durations.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Mild local burning, dryness. Rare/Severe: Secondary cutaneous infection.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Safe for short-term application on delicate skin. Do not apply to open tuberculous, fungal, or viral skin lesions.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered dermatologist or qualified medical practitioner before initiating, altering, or substituting any topical or systemic dermatological treatment.
Chlorzoxazone 500mg + Diclofenac 50mg + Paracetamol 325mg Tablets
Paracetamol (325mg/500mg) and Chlorzoxazone (250mg) Tablets is a centrally acting skeletal muscle relaxant and analgesic combination. Chlorzoxazone inhibits multi-synaptic reflex arcs in the spinal cord and subcortical areas of the brain, relieving painful skeletal muscle spasms. Paracetamol acts centrally to alleviate associated pain and discomfort. Indicated for acute, painful musculoskeletal conditions, muscle spasms, lumbago, torticollis, and strain/sprain trauma.
Diclofenac Gel 1.16% (Diclofenac Diethylamine)
Diclofenac Gel 1.16% (Diclofenac Diethylamine) is an evidence-based dermatological formulation. It acts by delivering targeted active therapeutic ingredients to cutaneous lesions to relieve skin pathology, restore barrier integrity, and manage dermatoses.
Serratiopeptidase 10mg + Diclofenac Sodium 50mg Tablets
Diclofenac Sodium/Potassium Tablets (50mg Gastro-Resistant, 75mg/100mg Prolonged Release) is an oral phenylacetic acid non-steroidal anti-inflammatory drug (NSAID) on the WHO Model List of Essential Medicines. It potently inhibits both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, halting prostaglandin synthesis, and also reduces intracellular concentrations of free arachidonic acid in leukocytes. Potassium salt provides rapid dissolution and quick pain relief; sodium prolonged-release provides steady 24-hour therapeutic coverage. Indicated for relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute musculoskeletal disorders, and acute migraine attacks.
Diclofenac Sodium Prolonged Release Tablets 100 mg
Diclofenac Sodium/Potassium Tablets (50mg Gastro-Resistant, 75mg/100mg Prolonged Release) is an oral phenylacetic acid non-steroidal anti-inflammatory drug (NSAID) on the WHO Model List of Essential Medicines. It potently inhibits both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, halting prostaglandin synthesis, and also reduces intracellular concentrations of free arachidonic acid in leukocytes. Potassium salt provides rapid dissolution and quick pain relief; sodium prolonged-release provides steady 24-hour therapeutic coverage. Indicated for relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute musculoskeletal disorders, and acute migraine attacks.